CNM-Au8 ® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) Clene (CLNN) plans to discuss the totality of the survival ...

In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...

ANOVA will tell you whether there is a statistically significant difference in the population means of three or more groups of data. But which means are different? Tukey’s will tell you that. Analysis ...

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that ...

SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of ...

- Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGARI ...